Keryx Biopharmaceuticals Inc - Key Opinion Leader Lunch: Iron Deficiency Anemia in Patients with Chronic Kidney Disease
שיחת ועידה Keryx Biopharmaceuticals Inc
Keryx Biopharmaceuticals Inc Conference call will be held on 31/05/2018. During the earnings conference call's session Keryx Biopharmaceuticals Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Keryx Biopharmaceuticals Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease. Our product, Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, that received marketing approval from the U.S. Food and Drug Administration, or FDA, in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. When discussing ferric citrate in the United States in reference to our marketed product, we will refer to it as Auryxia, when discussing it in the United States in reference to our compound, we will refer to it as ferric citrate, when discussing it in Japan, we will refer to it as Riona, and when discussing it in Europe, we will refer to it as Fexeric. We launched Auryxia in the United States in late December 2014.קרא עוד שיחת ועידה